Overuse of PPIs in patients at admission, during hospitalisation, and at discharge in a Terciary Spanish hospital

Current Clinical Pharmacology

Volumn 5, Issue 4, 2010, Pages 288-297

  Ramírez, Elena ^a   Lei, Su H ^a   Borobia, Alberto M ^a   Piñana, Enrique ^a   Fudio, Salvador ^a   Muñoz, Raúl ^a   Campos, Armando ^a   Carcas, Antonio J ^a   Frías, Jesus ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

(4 A 6) drug utilisation studies; Drug use; Drug drug interactions; Overuse; Proton pump inhibitors; Serious adverse drug reactions

Indexed keywords

PROTON PUMP INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; DRUG INTERACTION; DRUG USE; DRUG UTILIZATION; FEMALE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; OUTPATIENT; PRESCRIPTION; SPAIN; STATISTICS; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; DRUG INTERACTIONS; DRUG PRESCRIPTIONS; DRUG UTILIZATION; DRUG UTILIZATION REVIEW; FEMALE; HOSPITALIZATION; HOSPITALS, UNIVERSITY; HUMANS; INPATIENTS; MALE; MIDDLE AGED; OUTPATIENTS; PHYSICIAN'S PRACTICE PATTERNS; PROTON PUMP INHIBITORS; SPAIN;

EID: 79952279097     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488410793352067     Document Type: Article

References (62)

1. Batuwitage BT, Kingham JG, Morgan NE, Bartlett RL Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007; 83: 66-8.
2. Servicio de Andalucía de Salud. Áreas de mejora en el uso racional de medicamentos y criterios de calidad de prescripción. 2009. Informe justificativo de criterios de selección de medicamentos 2009, Anexo A. First ed. Grupo Multidisciplinar Asesor en Uso Racional del Medicamento del Servicio Andaluz de Salud. Sevilla 2009. Available at: http://www.dscadizlajanda.com/images/archivos/IBP.pdf [LMarch 9, 2010].
3. Barozzi N, Tett SE. Gastroprotective drugs in Australia: utilization patterns between 1997 and 2006 in relation to NSAID prescribing. Clin Ther 2009; 31(4): 849-61.
4. de Burgos Lunar C, Novo del Castillo S, Llorente Díaz E, Salinero Fort MA. Study of prescription indication of proton pump inhibitors. Rev Clin Esp 2006; 206(6): 266-70.
5. Pillans PI, Kubler PA, Radford JM, Overland V. Concordance between use of proton pump inhibitors and prescribing guidelines. Med J Aust 2000; 172:16-18.
6. Mat Saad AZ, Collins N, Lobo MM, O'Connor HJ. Proton pump inhibitors: a survey of prescribing in an Irish general hospital. Int J Clin Pract 2005; 59: 31-4.
7. Van Vliet EO, Otten HJ, Rudolphus A, et al. Inappropriate prescription of proton pump inhibitors on two pulmonary medicine wards. Eur J Gastroenterol Hepatol 2008; 20(7): 608-12.
8. Nardino R, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalised patients. Am J Gastroenterol 2000; 95: 3118-22.
9. Walker NM, McDonald J. An evaluation of the use of proton pump inhibitors. Pharm World Sci 2001; 23: 116-17.
10. Ntaios G, Chatzinikolaou A, Kaiafa G, Savopoulos C, Hatzitolios A, Karamitsos D. Evaluation of use of proton pump inhibitors in Greece. Eur J Intern Med 2009; 20(2): 171-3.
11. Pham CQD, Regal RE, Bostwick TR, Knauf KS. Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacother 2006; 40: 1261-6.
12. Wohlt PD, Hansen LA, Fish JT. Inappropriate continuation of stress ulcer prophylactic therapy after discharge. Ann Pharmacother 2007; 41(10): 1611-6.
13. Grant K, Al-Adhami N, Tordoff J, Livesev J, Barbezat G, Reith D. Continuation of proton pump inhibitors from hospital to community. Pharm World Sci 2006; 28(4): 189-93.
14. Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretoris during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2008; 27(11): 1110-21
15. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitors therapy and risk of hip fracture. JAMA 2006; 296(24): 2947-53.
16. Bajaj JS, Zadvornova Y, Heuman DM, et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 2009; 104(5): 1130-4.
17. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292: 2012-13.
18. Laheij RJ, Van Ijzendoorn MC, Janssen MJ Cansen JB. Gastric acid-suppressive therapy and community-acquired respiratory infections. Aliment Pharmacol Ther 2003; 18:847-51.
19. Yearsley KA, Gilby LJ, Ramadas AV, Kubiak EM, FOne DL, Allison MC. Proton pump inhibitor therapy is a risk factor for Clostridium-difficile associated diarrhoea. Aliment Pharmacol Ther 2006; 24: 613-19.
20. Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003; 54: 243-5.
21. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid suppressive agents and the risk of community acquired Clostridium difficile associated disease. JAMA 2005; 294: 2989-95.
22. Neal KR, Scott HM, Slack RC, Logan RF. Omeprazole as a risk factor for Campylobacter gastroenteritis: case-control study. BMJ 1996; 312: 414-15.
23. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors. Drugs 2003; 63: 2739-54.
24. Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 2006; 29(9): 769-84.
25. Rosemary J, Adithan C. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Curr Clin Pharmacol 2007; 2(1): 93-9.
26. Grupo de trabajo de la guía de práctica clínica sobre ERGE. Manejo del paciente con enfermedad por reflujo gastroesofágico (ERGE). Guía de práctica clínica. Barcelona: Asociación Española de Gastroenterología, Sociedad Española de Medicina de Familia y Comunitaria y Centro Cochrane Iberoamericano; 2007. Programa de Elaboración de Guías de Práctica Clínica en Enfermedades Digestivas, desde la Atención Primaria a la Especializada: 1. First ed. Elsevier Doyma, S.L. Barcelona 2007. Available at: http://www.guiasalud.es/GPC/GPC_08_ERGE_2007.pdf [L, 2010].
27. Grupo de trabajo de la guía de práctica clínica sobre dispepsia. Manejo del paciente con dispepsia. Guía de práctica clínica. Barcelona: Asociación Española de Gastroenterología, Sociedad Española de Medicina de Familia y Comunitaria y Centro Cochrane Iberoamericano; 2003. Programa de Elaboración de Guías de Práctica Clínica en Enfermedades Digestivas, desde la Atención Primaria a la Especializada: 3. First ed. SCM, S.L. Barcelona 2003. Available at: http://www.cdf.sld.cu/gpc/gpc_dispepcia.pdf. [L, 2010].
28. Dispepsia: Managing dyspepsia in adults in primary care. First ed. National Institute for Clinical Excellence. London 2004. Available at: http://www.nice.org.uk/guidance/CG17.[L, 2010].
29. Capellá D, Laporte JR. La notificación espontánea de reacciones adversas a medicamentos. In Laporte JR, Tognoni, G, Eds. Principios de Epidemiología del Medicamento 2nd ed. Barcelona, Masson-Salvat, 1993; pp. 147-170.
30. Noguerado AA, Rodríguez BR, Zelaya CP, et al. Use of acidsuppressive medications in hospitalized patients. An Med Interna 2002; 19(11): 557-60.
31. Martín-Echevarría E, Pereira JA, Torralba M, et al. Assessing the use of protrom pumps inhibitors in a internal medicine department. Rev Esp Enferm Dig 2008; 100(2): 76-81
32. Peura DA. Prevention of nonsteroidal anti-inflammatory drugassociated gastrointestinal symptoms and ulcer complications. Am J Med 117 (Supl. 5A) 2004: 63S-71S.
33. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002; (4): CD002296.
34. Mellemkjaer L, Blot WJ, Sorensen HT, et al. Upper gastrointestinal bleeding among users of NSAIDs: A population-based cohort study in Denmark. Br J Clin Pharmacol 2002; 53: 173-81.
35. Hawkey CJ. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 2000; 119: 521-35.
36. Goldstein JL. Who needs prophylaxis of nonsteroideal antiinflammatory drug-induced ulcers and what is optimal prophylaxis? Eur J Gastroenterol Hepatol 2000; 12 Suppl 1: S11-5.
37. Greenwald DA. Aging, the gastrointestinal tract, and risk of acidrelated disease. Am J Med 2004; 117 (Supl. 5A): 8S-13S.
38. Pilotto A, Franceschi M, Leandro G, et al. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004; 20: 1091-7.
39. Press Release European Medicines Agency update on review of non-selective NSAIDS. London, Doc. Ref. EMEA/378695/2006. 26 Sep 2006.
40. Abraham NS, Castillo DL, Hartman C. National mortality following upper gastrointestinal or cardiovascular events in older veterans with recent nonsteroidal anti-inflammatory drug use. Aliment Pharmacol Ther 2008; 28(1): 97-106.
41. Fries JF, Murtaq KN, Bennett M, Zatarain E, Lingala B, Bruce B. The rise and decline of nonsteroidal antiinflammatory drugassociated gastropathy in rheumatoid arthritis. Arthritis Rheum 2004; 50(8): 2433-40.
42. Mutlu GM, Mutlu EA, Factor P. Prevention and treatment of gastrointestinal complications in patients on mechanical ventilation. Am J Respir Med 2003; 2: 395-411.
43. Jung R, MacLaren R. Proton-pump inhibitors for stress ulcer prophylaxis in critically ill patients. Ann Pharmacother 2002; 36: 1929-37.
44. DePriest JL. Stress ulcer prophylaxis. Crit Care Med 2004; 32: 858-73.
45. Tryba M, Cook D. Current guidelines on stress ulcer prophylaxis. Drugs 1997; 54: 581-96.
46. Daley RJ, Rebuck JA, Welage LS, Rogers FB. Prevention of stress ulceration: Current trends in critical care. Crit Care Med 2004; 32: 2008-13.
47. Dellinger RP, Levy MM, Carlet JM, et al. International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. Crit Care Med 2008; 36(1):296-327.
48. Faisy C, Guerot E, Diehl JL, Iftimovici E, Fagon JY. Clinically significant gastrointestinal bleeding in critically ill patients with and without stress-ulcer prophylaxis. Intensive Care Med 2003; 29: 1306-13.
49. Kantorova I, Svoboda P, Scheer P, et al. Stress ulcer prophylaxis in critically ill patients: A randomized controlled trial. Hepatogastroenterology 2004; 51: 757-61.
50. Noguerado AA, Rodríguez BR, Zelaya CP, et al. Use of acidsuppressive medications in hospitalized patients. An Med Interna 2002; 19(11): 557-60.
51. Pilotto A, Franceschi M, Leandro G, et al. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004; 20(10): 1091-7.
52. Chryssostalis A, Marck G, Sibilia J, Chaussade S. Prevention of gastroduodenal complications in patients taking low-dose aspirin. Gastroenterol Clin Biol 2004; 28 (Spec. 3): C84-9.
53. Kimmey MB. Cardioprotective effects and gastrointestinal risks of aspirin: Maintaining the delicate balance. Am J Med 2004; 117 (Supl. 5A): 72S-8S.
54. Chryssostalis A, Marck G, Sibilia J, Chaussade S. Prevention of gastroduodenal complications in patients taking low-dose aspirin. Gastroenterol Clin Biol 2004; 28 (Spec. 3): C84-9.
55. Kimmey MB. Cardioprotective effects and gastrointestinal risks of aspirin: Maintaining the delicate balance. Am J Med 2004; 117 (Supl. 5A): 72S-8S.
56. Bhatt DL, Scheiman J, Abrahan NS, et al. American college of cardiology foundation task force on clinical expert consensus documents. ACCF/AHA 2008 expert consensus document on reducing the gastrointestinal risk of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Document. J Am Coll Cardiol 2008; 52(18): 1502-17.
57. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301(9): 937-44.
58. Conn HO, Poynard T. Corticosteroids and peptic ulcer: Metaanalysis of adverse events during steroid therapy. J Intern Med 1994; 236: 619-32.
59. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: Role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114: 735-40.
60. Castro FM, García DE, Larraona JL, et al. Efficacy of low-dose lansoprazole in the treatment of non-erosive gastrooesophageal reflux disease. Influence of infection by Helicobacter pylori. Rev Esp Enferm Dig 2006; 98(3): 170-9.
61. Garza GE, Giasi GE, Martínez VMA, et al. Helicobacter pylori erradication and its relation to antibiotic resistance and CYP2C19 status. Rev Esp Enferm Dig 2007; 99(2): 71-5.
62. Rey E, Moreno Elola-Olaso C, Rodríguez AF, Díaz-Rubio M. Impact of gastroesophageal reflux symptoms on health resource usage and work absenteeism in Spain Rev Esp Enferm Dig 2006; 98: 518-26.